Affibosy’s partner Biotest, a Germany-based biotherapeutic company, has exercised an option under the two companies’ ongoing collaboration.
“Biotest has finalized the research phase of the research license and option agreement we originally signed in 2015 and based on the preclinical results decided to exercise its option. Biotest now receives exclusive rights for further development and commercialization of an innovative new haemophilia product,” says David Bejker, CEO of Affibody. “We are delighted with this decision, which demonstrates the innovative nature and competitive strength of our Affibody technology.”
“Preclinical results so far with the Albumod technology are very promising and we believe in its potential for the development of improved protein drugs in Biotest’s therapeutic areas such as haemophilia,” says Dr Jörg Schüttrumpf, Senior Vice President Global Research Biotest.
Affibody will receive a license conversion fee and milestone payments as well as royalties.
